Optic nerve repair could treat glaucoma:
This article was originally published in Clinica
Executive Summary
Mice treated with Boston Life Sciences' central nervous system growth factor Axogenesis Factor 1 (AF1) have re-grown severed axons within the optic nerve, suggesting that AF1 could be used to treat blindness caused by glaucoma. Degenerative injury to the optic nerve destroys the vision of glaucoma sufferers. This is the first time that injection of a single nerve growth factor has resulted in optic nerve regeneration, says Boston Life Sciences. The company's chief scientific officer, Dr Marc Lanser said, "These exciting data suggest that AF1 has the potential to be a totally novel approach to the treatment of glaucoma."
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.